These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25916744)

  • 1. First evidence of PSMA expression in differentiated thyroid cancer using [⁶⁸Ga]PSMA-HBED-CC PET/CT.
    Verburg FA; Krohn T; Heinzel A; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1622-3. PubMed ID: 25916744
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrated
    Lütje S; Cohnen J; Gomez B; Grüneisen J; Sawicki L; Rübben H; Bockisch A; Umutlu L; Pöppel TD; Wetter A
    Nuklearmedizin; 2017 Jun; 56(3):73-81. PubMed ID: 28401244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT.
    Verma P; Malhotra G; Meshram V; Chandak A; Sonavane S; Lila AR; Bandgar TR; Asopa RV
    Clin Nucl Med; 2021 Aug; 46(8):e406-e409. PubMed ID: 33883490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ga-68-PSMA PET/CT for prostate cancer].
    Hellwig D; Moosbauer J; Eilles C
    Aktuelle Urol; 2014 Nov; 45(6):457-63. PubMed ID: 25518963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of a novel urea-based
    Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
    Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and preclinical evaluation of an Al
    Boschi S; Lee JT; Beykan S; Slavik R; Wei L; Spick C; Eberlein U; Buck AK; Lodi F; Cicoria G; Czernin J; Lassmann M; Fanti S; Herrmann K
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2122-2130. PubMed ID: 27329046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
    Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M
    Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
    Kabasakal L; Demirci E; Ocak M; Akyel R; Nematyazar J; Aygun A; Halac M; Talat Z; Araman A
    Nucl Med Commun; 2015 Jun; 36(6):582-7. PubMed ID: 25738559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of
    Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
    Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.
    Pfob CH; Ziegler S; Graner FP; Köhner M; Schachoff S; Blechert B; Wester HJ; Scheidhauer K; Schwaiger M; Maurer T; Eiber M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1962-70. PubMed ID: 27207281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intense PSMA-expression using (68)Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis.
    Rischpler C; Maurer T; Schwaiger M; Eiber M
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):193-194. PubMed ID: 26502982
    [No Abstract]   [Full Text] [Related]  

  • 13. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
    Ray Banerjee S; Chen Z; Pullambhatla M; Lisok A; Chen J; Mease RC; Pomper MG
    Bioconjug Chem; 2016 Jun; 27(6):1447-55. PubMed ID: 27076393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paget Disease: A Potential Pitfall in PSMA PET for Prostate Cancer.
    Blazak JK; Thomas P
    Clin Nucl Med; 2016 Sep; 41(9):699-700. PubMed ID: 27405026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The
    Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
    Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
    J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Image of the Month: Multifocal 68Ga Prostate-Specific Membrane Antigen Ligand Uptake in the Skeleton in a Man With Both Prostate Cancer and Multiple Myeloma.
    Rauscher I; Maurer T; Steiger K; Schwaiger M; Eiber M
    Clin Nucl Med; 2017 Jul; 42(7):547-548. PubMed ID: 28368889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.
    Afshar-Oromieh A; Haberkorn U; Eder M; Eisenhut M; Zechmann CM
    Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):1085-6. PubMed ID: 22310854
    [No Abstract]   [Full Text] [Related]  

  • 19. Validation of a [Al
    Al-Momani E; Israel I; Samnick S
    Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 68Ga-Labeled Anti-Prostate-Specific Membrane Antigen Peptide as Marker for Androgen Deprivation Therapy Response in Prostate Cancer.
    Schlenkhoff CD; Gaertner F; Essler M; Hauser S; Ahmadzadehfar H
    Clin Nucl Med; 2016 May; 41(5):423-5. PubMed ID: 26859213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.